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Objective: Aortic valve replacement (AVR) is the standard therapy in patients with symptomatic aortic stenosis (AS).
In high surgical risk patients, alternative therapeutic options to medical treatment (MT) such as trans-catheter aortic
valve implantation (TAVI) or balloon aortic valvuloplasty (BAV) have been proposed. In this study we evaluated
whether treatment assignment influences per se the prognosis of these subjects.
Patients and methods: Criteria for treatment assignment were based on patient’s clinical conditions, Logistic
EuroSCORE and other co-morbidities ignored by EuroSCORE. Due to baseline clinical differences between patients
with diverse treatment assignment, we used propensity score matching to achieve balance.
Results: 368 patients were studied: 141 underwent AVR, 127 TAVI, 49 BAV and 51 MT. 84 events (deaths for all
causes) occurred during 14 months of follow-up: 11 AVR (8%), 26 TAVI (20%), 18 MT (35%), 29 BAV group (59%).
Traditional Cox analysis identified treatment assignment as independent predictor of events (HR 1.82 [CI 1.10-3.25])
together with lower left ventricular ejection fraction, impaired renal function and history of heart failure. Matched
Cox analysis by propensity score confirmed treatment assignment as an independent prognosticator of events (HR
1.90 [CI 1.27-2.85]), and showed similar rate events in TAVI and AVR patients, while it was significantly increased in
BAV and MT patients.
Conclusions: Treatment assignment may influence outcome of symptomatic patients with AS.
Keywords: Aortic stenosis, Aortic valve replacement, TAVI, Balloon aortic valvuloplasty, PrognosisIntroduction
Suggestions for surgery have been clearly defined for pa-
tients with aortic stenosis (AS), and there is a consensus
that intervention is mandatory in symptomatic patients
[1], whose prognosis radically worsens once valve disease
symptoms arise. Although aortic valve replacement (AVR)
is the standard therapy, in patients with high surgical risk,
alternative therapeutic options to medical treatment (MT)
such as trans-catheter aortic valve implantation (TAVI) or
balloon aortic valvuloplasty (BAV) have been recently in-
troduced [2]. However, the impact on clinical outcomes is
very difficult to assess and compare with conventional* Correspondence: gcioffi@villabiancatrento.it
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unless otherwise stated.AVR mainly because of the clinical heterogeneity of the
patients in terms of co-morbidities and frailty [3]. Beside
patient’s conditions, the treatment assignment, commonly
based on a multi-disciplinary evaluation and supported by
several currently used risk scores, might have a clinically
relevant effect on the outcomes.
Accordingly, in this study, we analyzed and compared
clinical features and mid-term outcomes of a large cohort
of patients with symptomatic AS assigned to each treat-
ment (AVR, TAVI, BAV and MT) and assessed whether
the treatment assignment per se had an influence on the
prognosis of these patients.Patients and methods
The study population included subjects with symptomatic
severe AS (defined as indexed aortic valve area < 0.6 cm2/his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tients underwent a comprehensive evaluation including
clinical history, physical examination, blood sample,
electrocardiogram, chest radiogram, echocardiography,
computed tomography of the chest, coronary arteriog-
raphy and aortography. Clinical risk assessment was
performed with the Logistic EuroSCORE [4]. Treatment
assignment was the result of a consensus of clinical car-
diologists, interventional cardiologists and cardiac sur-
geons shared with each patient. Criteria for treatment
assignment were based on patient’s clinical conditions,
Logistic EuroSCORE and several other coexisting condi-
tions ignored by EuroSCORE that impeded a standard-
ized approach in place of a made personal consensus
stated for each patient. Written informed consent was
obtained from all study participants. The Institutional
Ethic Committee approved the study protocol, which con-
forms to the ethical guidelines of the 1975 Declaration of
Helsinki.
Echocardiography
Left ventricular (LV) chamber dimensions and wall thick-
nesses were measured according the recommendations of
the American Society of Echocardiography. Relative wall
thickness was calculated as two times the posterior wall
thickness/LV diastolic diameter ratio and used as index of
LV geometry. Index ≥0.43 was indicative of concentric
geometry (the 97.5 percentile in normal population) [5].
LV mass was calculated using the Devereux’s formula [6]
and indexed for body surface area. LV volumes and ejec-
tion fraction (LVEF) were measured by biplane Simpson’s
method. Aortic valve area (AVA) was measured by the
standard continuity equation method and indexed for
body surface area. Ascending aorta dilation was defined as
one or more ascending aorta segment diameter ≥ 40 mm,
and classified as mild to moderate if >40 but <50 mm
and severe if >50 mm. Porcelain aorta was diagnosed by
computed tomography in presence of diffuse plate-like
calcification involving the ascending aorta precluding
cannulation or cross clamping of the ascending aorta.
Definition of comorbidities
Kidney disease was defined as glomerular filtration rate
(GFR) <60 ml/min/1.73/m2 [7]. Chronic obstructive
pulmonary disease (COPD) was recognized according to
published cut off values (GOLD investigators) [8].
Systemic arterial hypertension was considered when
blood pressure >140/90 mmHg or in presence of anti-
hypertension medical therapy. Hypercholesterolemia
was diagnosed if serum cholesterol was > 200 mg/dl or
in presence of pharmacological therapy. We also took
into account as co-morbidity the presence of cancer (as
history and/or coexistent with AS), we calculated the
Charlson score index taken as pointer of burden ofdisease by summing 19 categories of co-morbidities [9],
and the Katz score as specific index of frailty [10].
Statistical analysis
Data are reported as mean values ±1 SD. Between-group
comparisons of categorical and continuous variables were
performed by χ2 test and analysis of variance (ANOVA),
respectively. Primary end-point was considered all-cause
mortality including in-hospital post-operative death. In
order to identify the predictors of all-cause mortality, Log
cumulative hazard functions were initially computed by
univariate and multivariate Cox proportional hazards
analyses, in which all recruited patients were included.
Variables which were significantly related to the primary
end-point in univariate tests (p < 0.05) were included in
the multivariate model. The treatment assignment variable
was modeled as categorical. It was categorized in 4 classes
and codified as 1 = AVR, 2 = TAVI, 3 =MT and 4 = BAV.
No pooling was done among patients who underwent
TAVI, MT or BAV. Thus, the HR emerged by matched
Cox model for the treatment assignment variable was not
referred to a specific class vs the others, but to a signifi-
cant inter-class difference.
Estimation of propensity scores and matching
Due to the substantial differences in baseline patients’
features between AVR patients and those assigned to
other treatments, we used propensity score matching to
achieve balance. The propensity score is the conditional
probability of receiving an exposure (e.g. different treat-
ment assignment) given a vector of measured covariates,
and can be used to adjust for selection bias when assessing
causal effects in observational studies [11]. We estimated
propensity scores for treatment assignment for symptom-
atic AS for all patients using a non-parsimonious multi-
variable logistic regression model. In that model, the
following variables which could potentially influence both
the treatment assignment and the clinical outcome were
included as covariates: age, Charlson co-morbidity index,
Logistic EuroSCORE, history of heart failure, LVEF,
COPD, GFR and AVA (measured before the treatment as-
signment). We then used a Gower’s procedure to match
each patient assigned to AVR (considered the gold stand-
ard treatment) with another patient who was assigned to
an alternative treatment, but who had a very similar pro-
pensity score, thus matching 127 AVR patients (90% of
the 141 patients who underwent AVR) to 127 patients
who were assigned to another treatment: 79 TAVI, 14
BAV and 34 MT. Residual imbalances in baseline covari-
ates between treatment groups after propensity score
matching were assessed by estimating absolute standard-
ized differences, expressed as a percentage of the pooled
standard deviation. Our propensity score matching re-
duced absolute standardized differences for all observed
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ing substantial improvement in covariate balance across
the groups. For the comparison of the propensity score
matched groups, we used a matched Cox model.
Survival rate was analyzed by the Kaplan-Meier method
and survival curves were compared by the log-rank test. A
p value < 0.05 was considered statistically significant. All
analyses were performed using SPSS for Windows version
19.0 (SPSS Inc. Chicago, Illinois, USA).
Results
Study population
368 subjects with symptomatic AS (71% had at least an
episode of congestive heart failure, 16% of syncope, 26%
angina pectoris) were consecutively recruited in the
present study from June 2007 to October 2008. Their
mean age was 78 ± 10 years, 42% females, mean AVA
was 0.32 ± 0.12 cm2/m2 with a peak trans-aortic peak
valve gradient of 80 ± 23 mmHg. The prevalence of
hypertension was 75%, kidney disease 54%, chronic atrial
fibrillation 33%, diabetes mellitus 25%, COPD 23%,
porcelain ascending aorta 3%, history of and coexistent
cancer 14% and 4%, respectively. The mean LVEF was
50% ± 8, the mean Logistic EuroSCORE was 25%.
141 patients (38%) underwent AVR (mechanical pros-
thesis in 100, tissue in 41 patients), 127 (35%) TAVI, 49
(13%) BAV and 51 (14%) were managed by optimized
pharmacological treatment (group MT). The main vari-
ables of study patients divided according to the treat-
ment assignment are shown and compared in Table 1.
Group AVR included the youngest patients, prevalently
females with better NYHA functional class and renal
function, lower prevalence of history of heart failure,
lower pulmonary artery systolic pressure and lower Euro-
score than all the other groups. The groups BAV and MT
had the worse NYHA functional class and renal function.
Mean value of Logistic EuroSCORE was significantly dif-
ferent between the groups ranging from 16% in AVR
group to 33% in BAV group (p < 0.001).
The distribution of candidates to the four treatment
assignments allocated according to the quartiles of
Logistic EuroSCORE is shown in Figure 1. Patients who
were not at high risk for AVR according to the Euro-
SCORE (lower than 20%) were 55 (42%) in the TAVI
group, 13 (24%) in the BAV group, and 20 (39%) in the
MT group. Reasons for which these patients did not
undergo AVR are listed in Table 2. Patients belonging to
MT group had all absolute clinical and/or technical
contraindication to any procedure of valve replacement or
dilatation, independent to Logistic EuroSCORE.
Outcome
Follow-up information was available in all 368 patients.
At the end of follow-up (mean 14 ± 9 months, range 0–40), 284 patients (77%) were alive. During this period 84
events (all-cause deaths) (23%) were recorded in this full
(pre-match) cohort. The cumulative event-free survival
in the whole study population was 85% at 1 year, 69% at
2 years, 50% at 3 years. The primary end-point occurred
in 11 of 141 AVR patients (8%), in 26 of 127 TAVI pa-
tients (20%), in 18 of 51 MT patients (35%) and in 29 of
49 BAV patients (59%) (overall p ≤ 0.03) (Figure 2). Simi-
lar trend was observed in the subgroups of patients
without high EuroSCORE: all-cause mortality occurred
in 5% of AVR group, 20% in TAVI group, 35% in BAV
group and 31% in MT group. In comparison with AVR,
TAVI patients were older, had higher NYHA functional
class and EuroSCORE, lower GFR and AVA. In order to
assess the outcome differences related to various treat-
ment choices in a relatively similar status of underlying
clinical conditions, we compared the events rate of four
different treatment options in the same EuroSCORE
quartiles (Figure 3). No difference in mortality rate was
found between patients of the four study group in the
lowest two quartiles of EuroSCORE, while a significantly
higher mortality rate than the other groups was docu-
mented in patients undergoing BAV classified in the
upper two EuroSCORE quartiles.
Considering the subgroups of patients without high
EuroSCORE who did not undergo AVR, all-cause death
occurred in 16 out of 88 patients (18%): 9 of 55 TAVI
patients (16%), 2 of 13 BAV patients (15%), and 5 of 20
MT patients (25%).
Follow-up was significantly shorter in BAV (9.0 ±
8.1 months) and MT groups (8.1 ± 7.2 months) (p = ns
between BAV and MT group) than in TAVI (13.9 ±
10.2 months) and AVR (19.2 ± 8.4 months) groups (p <
0.05 between the first two groups and the second ones
and between TAVI and AVR) due to the much higher
incidence of events in the first two groups. Among pa-
tients who died during the follow up, the mean time
from enrolment and the clinical event was 10.7 ±
8.2 months in AVR patients, 6.8 ± 5.3 in TAVI patients
(p < 0.05 vs AVR), 6.3 ± 4.9 in MT patients (p < 0.05 vs
AVR), and 4.8 ± 3.3 in BAV patients (p < 0.05 vs all).
Cardiac aetiology could be identified in 50 of 84 deaths
(59.5%). The reasons were listed in Table 3. Cardiac deaths
occurred more frequently in the BAV (24 of 29 = 83%) and
MT (13 of 18 = 72%) groups than in the AVR (4 of 11 =
36%) and TAVI (9 of 26 = 35%) groups.
Predictors of adverse outcome
Patients who had an adverse clinical event were older,
had a worse functional class and renal function, received
less frequently angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers (ACEi/ARB) and beta-
blockers, had a reduced AVA and LVEF, and had a more
frequent history of COPD and heart failure than those









• Age (years) 72 ± 10 83 ± 8* 84 ± 9* 81 ± 7*
• Female gender (%) 52 32 49§ 29*#
• Hypertension (%) 77 75 69 73
• Diabetes (%) 27 25 20 25
• Atrial fibrillation (%) 27 39 28 37
• NYHA function class (1–4 scale) 2.3 ± 0.8 2.6 ± 0.6* 2.9 ± 0.8*§ 2.9 ± 0.8*§
• History of heart failure (%) 60 73* 88*§ 76*
• Chronic obstructive pulmonary disease (%) 16 22 39*§ 25
• Left bundle branch block (%) 8 17* 20* 16*
• Kidney disease (%) 32 65* 71* 71*
• Glomerular filtration rate (ml/min/1.73) 73 ± 26 54 ± 23* 47 ± 26*§ 48 ± 28*§
• Haemoglobin (g/dl) 11.7 ± 1.8 11.9 ± 1.5 11.8 ± 1.4 11.9 ± 1.6
• Serum total colesterol (mg/dl) 162 ± 45 184 ± 47* 162 ± 29§ 159 ± 38*
• Charlson comorbidity index 2.1 ± 1.5 3.5 ± 1.7* 3.5 ± 1.7* 3.7 ± 2.0*
• Katz score 2.8 ± 1.7 3.8 ± 1.9* 3.8 ± 1.9* 4.2 ± 2.2*
• EUROSCORE 16 ± 12 28 ± 18* 33 ± 18* 31 ± 20*
• LV relative wall thickness 0.55 ± 0.11 0.55 ± 0.11 0.55 ± 0.14 0.56 ± 0.13
• LV mass (gr/m2) 209 ± 56 217 ± 59 541 ± 72*§° 207 ± 71#
• LV end-diastolic diameter (mm) 50.7 ± 0.8 50.7 ± 0.8 52.3 ± 0.9 50. ± 0.9
• LV end-diastolic volume (ml) 139 ± 69 141 ± 69 155 ± 79 132 ± 67
• LV ejection fraction (%) 53 ± 11 51 ± 12 41 ± 11*§° 50 ± 10#
• Pulmonary artery systolic pressure (mmHg) 38 ± 11 43 ± 14* 47 ± 15*§° 43 ± 12*
• Aortic valve area (cm2/m2) 0.41 ± 0.10 0.35 ± 0.08*° 0.34 ± 0.12*° 0.42 ± 0.13§#
• Trans valve area peak gradient (mmHg) 79 ± 24 86 ± 22* 71 ± 27§ 76 ± 24§
• Biscuspid aortic valve (%) 8 1* 4 6
• Beta-blockers (%) 42 28* 21* 35
• ACE-inhibitors/ARBs (%) 65 67 37*§° 65#
• Diuretics (%) 70 83* 95* 75
• Statins (%) 46 53 45 63
• Warfarin (%) 80 60* 55* 45*
ACE = angiotensin-converting enzyme; ARB = angiotensine receptor blockers; AVR = traditional surgical aortic valve replacement; BAV-baloon aortic valvuloplasty;
LV = left ventricular; MT =Medical Therapy; HYHA = New York Heart Associations; TAVI = tanscatheter aortic valve implentaions..
p < 0.05 vs AVR = *; vs TAVI = §; vs BAV = #; vs MT = °.
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sociated with adverse events.
Consistent with the results of univariate model, Cox
proportional hazard analysis included age, AVA, NYHA
functional class, GFR, COPD, history of heart failure,
LVEF fraction, peripheral artery disease, cancer, Euro-
SCORE, Charlson comorbidity index, Katz score, ACEi/
ARB treatment, beta-blocker treatment and the treat-
ment assignment to the AS. We also built a categorical
variable named “absolute contraindication to AVR” (yes
vs no) for selecting patients who did not undergo AVR
due to anatomic or technical reasons independent to the
logistic EuroSCORE value. This variable was forced intothe model. This analysis identified the treatment assign-
ment as a strong predictor of adverse outcome inde-
pendent of lower LVEF, lower GFR, history of heart
failure and absolute contraindication to AVR (Table 4).
Propensity-matched analysis
After matching, patients who underwent AVR (n = 127)
and those who did not (n = 127) were balanced in all of
measured baseline covariates: age 80 ± 6 vs 81 ± 7 years
(p = 0.24), Charlson co-morbidity index 3.3 ± 1.5 vs 3.7 ±
1.6 (p = 0.09), Katz score 3.3 ± 1.3 vs 3.6 ± 1.6 (p = 0.11),
history of heart failure 70% vs 81% (p = 0.17), EuroSCORE
25 ± 1.5 vs 29 ± 21 points (p = 0.09), LVEF 51% ± 12 vs
Figure 1 Distribution of the 368 candidates to the four therapeutic options according to the quartiles of Euroscore. AVR = aortic valve
replacement; TAVI = trans-catheter aortic valve implantation; BAV = balloon aortic valvuloplasty; MT =medical therapy.
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58 ± 24 vs 56 ± 18 ml/min/1.73 m2 (p = 0.49), AVA 0.39 ±
0.10 vs 0.38 ± 0.10 cm2/m2 (p = 0.33), respectively. All
these variables were also similar between patients who
underwent TAVI, BAV and MT. The primary end-pointTable 2 Reasons for which aortic valve replacement was
excluded as therapeutic option in patients without high
Euroscope who underwent treatment allocation to
transcatheter valve implantations (TAVI = 55 patients),
baloon aortic valvuloplasty (BAV = 13 patients),















14 10 2 2
Porcelain ascending
aorta
11 10 0 1
Severe chronic kidney
disease




5 3 2 0
Previous coronary-aortic
by-pass graft
3 2 0 1
Refuse to undergo
surgery
4 1 2 1
Hepatic cirrhosis 3 3 0 0
Thoracic deformation 2 1 1 0
Sever ascending aorta
dilatation
1 1 0 0
Cancer 2 0 1 1
Previous stroke 1 0 0 1occurred in 46 patients: 11 of 127 AVR patients (9%), in
10 of 79 TAVI patients (13%), in 7 of 14 BAV patients
(50%) and in 18 of 34 MT patients (53%). The independ-
ent association between treatment assignment and mor-
tality for all causes that emerged by the traditional Cox
regression analysis adjusted for all baseline covariates
remained strong and significant when adjusted for pro-
pensity scores (HR, 1.90, 95% CI, 1.27–2.85; p = 0.002).
Matched Cox analysis by propensity score showed similar
rate events in TAVI and AVR patients, while it was signifi-
cantly increased in BAV and MT patients (Figure 4).
Discussion
The main and original finding of our experience is that
treatment assignment significantly influences outcome
of symptomatic patients with AS independently of the
traditional well-known prognosticators. A first consider-
ation deriving from the results of our study is that the
clinical features of symptomatic patients with severe AS
markedly differ in term of age, functional class, LVEF,
co-morbidities, frailty and medical therapy in relation to
the treatment assignment. Patients assigned to AVR
were younger, had a better clinical presentation and re-
duced operative risk than patients assigned to the other
treatments. This is an expected finding if we consider
that AVR represents, as of today, the standard of care
for symptomatic patients with severe AS while TAVI,
BAV and MT have to be considered as a secondary rem-
edy. In our practice, the main reason for choosing alter-
native approaches to AVR was the high surgical risk
calculated by Logistic EuroSCORE. However, a signifi-
cant proportion of subjects who had not a high risk for
AVR (EuroSCORE lower than 20%) underwent TAVI
(42%), BAV (24%) and MT (39%), suggesting other fac-
tors contributed to the treatment assignment. This result
Figure 2 Event-free survival curves of the full (pre-match) cohort of patients (n = 368) with symptomatic aortic stenosis that underwent
AVR, TAVI, BAV and MT (see Figure 1 for the abbreviations).
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spite of encouraging clinical outcomes even among sub-
jects with high EuroSCORE, up to one-third of eligible
patients for AVR do not undergo this procedure [12,13].
Differently to the other studies, in our practice the pres-
ence of severely depressed LVEF did not lead to desist
from AVR in any patient. Not even the presence of
cancer, hepatic chronic disease and surgical technical
difficulties could substantially condition the treatment
assignment, which was, instead, strongly influenced by
the presence of severe COPD, severe renal disease, por-
celain ascending aorta and advanced age. Whereas theFigure 3 Incidence of all-cause mortality in the same EuroSCORE quafirst three conditions objectively represent prohibitive
obstacles for the surgical team and have a well-known
negative impact on clinical outcomes [1,14], the last one
is questionable as reason to preclude AVR [14,15] for
symptomatic severe AS. More recently, Grossi et al. [14]
demonstrated that Logistic EuroSCORE greatly over-
predicted mortality in the elderly patients, reporting a
five-year survival of 72%, unlike suggestions from earlier
EuroSCORE analyses. Accordingly, in our scenery, 30 of
88 patients (34%) without high EuroSCORE eligible for
AVR have been assigned to an alternative treatment just
cause of advanced age, signifying older age as the mostrtiles for the four different treatment options.
Table 3 The reasons of cardiac and non-cardiac deaths
occurred in each study group
Reasons AVR TAVI BAV MT
Cardiac deaths (n = 50)
Sudden death (n = 28) 2 4 10 12
Cardiogenic shock (n = 11) - - 10 1
Chronic pump failure (n = 5) 1 1 3 -
Cardiac tamponade (n = 3) - 3 - -
Chronic pump failure (n = 5) 1 1 3 -
Cardiac tamponade (n = 3) - 3 - -
Acute massive aortic regurgitation (n = 1) - - 1 -
Pulmonary emolism (n = 1) - 1 - -
Endocarditis (n = 1) 1 - - -
Non Cardiac deaths (n = 34)
Cancer (n = 10) 2 4 2 2
Sepsis (n = 9) 2 6 1 -
Complicated hip fracture (n = 3) - 3 - -
Canchexia (n = 2) - - 1 1
Hepatic cirrhosis (n = 2) - 1 - 1
Stroke (n = 1) - 1 - -
Unknown (n = 7) 3 2 1 1
Table 4 Variables independently related to adverse events in
proportional hazard univariate and multivariate analysis




LV ejection fraction (%) 44 ± 14 vs 52 ± 13
History of heart failure (%) 87 vs 66
GFR (ml/min/1.73/m2) 43 ± 24 vs 63 ± 27
Absolute contraindication to AVR (%) 57 vs 27
Treatment assignment for AS -
Age (year) 83 ± 8 vs 77 ± 9
NYHA functional class (1–4) 2.8 ± 0.7 vs 2.5 ± 0.07
Charlons co-morbidity index 3.9 ± 1.7 vs 2.7 ± 1.8
Katz score 4.1 ± 1.8 vs 3.1 ± 1.9
Aortic valve area (cm2/m2) 0.61 ± 0.18 vs 0.69 ± 0.20
Peripheral artery disease (%) 10 vs 3
COPD (%) 36 vs 18
Cancer (%) 8 vs 2
EuroSCORE (points) 34 ± 22 vs 22 ± 18
ACEi/ARB (%) 49 vs 66
Beta-blockers (%) 22 vs 37
AS = aortic stenosis; AVR = aortic valve replacement; COPD = chronic obstructive pu
New York Heart Association.
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tional surgery. Of note, in this large subgroup of 88 pa-
tients without high EuroSCORE but perceived as unfitting
for AVR, the cumulative incidence of all-cause death was
19%, a percentage not significantly different from that
found in the remaining 280 patients (68 deaths = 24%),
half of them being subjects with low EuroSCORE who
underwent AVR. No difference in the cumulative inci-
dence of all-cause death was found in patients with and
without high EuroSCORE assigned to MT or TAVI treat-
ment. However, the most striking point regards patients
assigned to BAV treatment, conceived too ill for TAVI.
The outcomes of BAV were so poor because the technique
resulted ineffective or even dangerous in patients who
were very old, with the lowest values of LVEF and GFR
and the highest values of pulmonary artery hypertension,
NYHA functional class and LV mass. Considering the
poor clinical presentation and the large number of co-
morbidities of BAV patients, the cumulative incidence of
all-cause death was quite low (15%) in the subgroup with-
out high EuroSCORE, while it was 4-fold higher in the
whole BAV group, showing an unacceptable event rate of
59%, significantly higher than that found in MT patients.
Notably, the large majority of these events (83%) were car-
diac deaths. These findings have to be food for thought
and critical revision of our therapeutic approach, and are
accountable, at least in part, for the dominant and novel
result of the present study, which is the demonstration
that the treatment assignment per se had an independentthe total study populations (368 patients): Cox
nivariate
alysis
CI p HR multivariate
analysis
CI p
0.96 0.95-0.98 <0.001 0.98 0.96-0.99 0.003
1.65 1.28-2.13 <0.001 2.25 1.16-4.34 0.02
0.98 0.97-0.99 <0.001 0.98 0.97-0.99 0.01
3.58 2.16-5.94 <0.001 2.39 1.35-4.22 0.003
2.01 1.62-2.62 <0.001 1.82 1.10-3.25 <0.001
1.02 1.01-1.03 0.004 1.05 0.99-1.09 0.07
2.02 1.41-2.90 <0.001 1.05 0.81-1.36 0.69
1.29 1.18-1.42 <0.001 1.25 0.90-1.57 0.60
1.33 1.11-1.55 <0.001 1.31 0.85-1.62 0.52
1.44 0.45-4.41 0.52 0.18 0.01-2.82 0.22
3.63 1.32-9.99 0.01 2.36 0.71-7.84 0.16
2.48 1.45-4.25 0.01 1.02 0.36-2.84 0.97
1.90 1.11-3.25 0.02 1.07 0.49-2.33 0.87
1.03 1.02-1.04 <0.001 0.99 0.98-1.01 0.63
0.48 0.28-0.81 0.006 0.56 0.31-1.01 0.08
0.48 0.26-0.88 0.02 0.57 0.29-1.15 0.12
lmonary disease; GFR = glomerular filtration rate; LV = left ventricular; NYHA =
Figure 4 Event-free survival curves of 254 patients with symptomatic aortic stenosis selected and matched by propensity score
analysis who underwent AVR (n = 127), TAVI (n = 79), BAV (n = 14) and MT (n = 34) (see Figure 1 for the abbreviations).
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atic severe AS.
Considering MTgroup with reference to the natural his-
tory of AS, in our setting we found that TAVI significantly
improved survival with a 1-year, with a similar benefit on
all-cause mortality to AVR group, when the study popula-
tion was considered after propensity score matching. Lit-
erature data on the comparison between AVR and TAVI
are limited and apparently irreconcilable. Piazza et al. [16]
found a 30-day mortality significantly higher after TAVI
than AVR (9.6% vs 2.3%, respectively). On the contrary,
Walther et al. [17] and Descoutures et al. [18] reported
similar survival rates between the two groups at 1-year
(TAVI 73% vs AVR 69%) and 6-month follow-up (both
groups 100%), respectively. Also Wenaweser et al. [3], fol-
lowing patients for a longer period (30 months) found
similar rates of all-cause mortality for AVR (22.4%) and
TAVI (22.6%) patients. Finally, PARTNERS’s investigators
[19] definitively demonstrated in a randomized population
of patients with AS who are at high risk for operative
complications and death (mean age 84 years, mean Euro-
SCORE 29%), that surgical AVR and TAVI were associated
with similar mortality at 30 days (6.5% vs 3.4%) and 1 year
(26.8% vs 24.2%), and produced similar improvements in
cardiac symptoms.
According to these results and our finding indicating
treatment assignment as independent predictor of all-
cause mortality, the opened question is: could some
BAV and MT patients be safety referred to AVR, in par-
ticular some of them excluded just for advanced age?
Such question turns into doubt if we consider the recent
results of the SOURCE registry [20], in which mortality
was powerfully influenced by the EuroSCORE (below20% in one-third of partecipants) that emerged as its
strongest predictor.
Specific considerations have to be made for the BAV ap-
proach. We found an excessive mortality (near two third
of candidates) in patients undergoing BAV and classified
in the two upper quartiles of EuroSCORE, while mortality
rate was similar to the other therapeutic approach in less
compromised patients. In line with our data, several au-
thors showed unsatisfactory results when this treatment
was proposed alone as palliative therapy [21,22]. Ben-Dor
et al. [21] showed that survival after BAV alone was 50%
at 6-month follow up. Tissot et al. [22] found no differ-
ence in survival between MT and BAV alone (p = 0.36),
while showed similar good mid-term outcomes between
the primary TAVI/AVR and bridge BAV to TAVI/AVR
(p = 0.08). According to our results, indicating that in
BAV patients the adverse clinical events occur early
after the procedure (mean time 4.8 months), these au-
thors re-evaluated the patients around one month after
BAV for a final decision and were able to successfully
replace the aortic valve in 74% of cases (46% TAVI and
28% AVR).
Study limitations
Our study has some limitation. First, despite the total
study population included an appropriate number of sub-
jects (n = 368), the number of patients considered for the
comparison of the propensity score matched groups was
quite limited in the BAV and MT subgroups, leading to a
reduced statistical power for the comparison of treatment
groups. Second, we presented a mono-centric clinical ex-
perience in which novel aspects on the management of
patients with symptomatic severe AS had to be overcome,
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proaches. Second, we categorized some co-morbidities
(yes vs no) which could be graded for intensity and/or
clinical impact (i.e. COPD, stroke). The concern is that
treatment assignment more than a really valid predictor
of adverse outcome, could represent a measure of
EuroSCORE, cause of healthier patients were assigned
to AVR procedure. However, we gathered information
on the patient’s “comorbidities” (Charlson co-morbidity
index), “frailty” (Katz score), and analyzed the absolute
contraindications to AVR. These are consistent indexes
voicing the charge of co-morbidities and weighting the
complexity of patient’s status in terms of physical needs,
psychological burdens and risk of surgical failure. By our
analysis, it emerged that the amount of co-morbidities
and the degree of frailty, which were quite low in AVR pa-
tients, were similarly higher in patients who underwent
TAVI or BAV or MT and did not influence outcome. On
the contrary, a history of heart failure, LV and renal dys-
function accounted for patient’s frailty better than more
composite indexes (i.e. Charlson, Katz, EuroSCORE)
and predicted long-term mortality as well as the treat-
ment assignment.
Final considerations and conclusions
In our experience the treatment assignment influences
outcome of symptomatic patients with AS, so that cri-
teria on treatment modality for these patients have to be
called into question. Alternative treatments to AVR have
been recently introduced in clinical practice and, by our
results, they seem to be overused. Lacking stringent cri-
teria for each treatment modality and data on long-term
follow-up, the new scenery may puzzle cardiologists who
have to come to a decision often based on individual ex-
perience and emotional feelings more than on solid and
standardized protocols and scientific statements. Analyz-
ing our data, it emerged the paradoxical occurrence of an
invasive procedure (BAV) which was inferior to MT in
terms of all-cause mortality. For most of these patients the
choice of BAV in place of MT appears critical considering
the clinical characteristics of patients assigned to the inva-
sive approach.
Furthermore, most of the “absolute” contraindications
to AVR appear to be “relative” contraindications, so that
many candidates to surgery were assigned to alternative
treatments and deprived of the safest therapeutic option
available up today. Thus, our experience visibly springs
from the current pattern of available treatments, the as-
signment of which to the single individual represents
one of the most stimulating challenge for the cardiolo-
gists. They have to take into account at the same time
prognosis, quality of life, patient’s expectancies, cost/
benefit ratios, site selection, center and physician experi-
ence and suggestions from the red-hot expert consensusdocument on TAVI [23]. The results of our study lead to
conclude that if there is no serious contraindication (low
life expectancy, very high EuroSCORE or serious tech-
nical difficulty), the patients should be forced to AVR.
Waiting for the clearer therapeutic indications deriving
by the results of ongoing clinical trials, this maybe the
time of better safe than sorry.
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